AVBP stock forecast, quote, news & analysis

Key Takeaways

• ArriVent BioPharma (AVBP) shares have declined roughly 45% over the last 30 days, from about $28.45 to near $15.70.
• The selloff was driven primarily by the October 6, 2026 failure of the Phase 3 FURVENT trial of lead drug candidate firmonertinib in first-line EGFR exon 20 insertion-mutated non-small cell lung cancer.
• Firmonertinib's 240 mg dose delivered a median progression-free survival of 11.0 months versus 9.5 months for chemotherapy, a difference that did not reach statistical significance.
• Analysts responded by cutting price targets and largely removing the exon 20 insertion opportunity from their valuation models, redirecting focus to the PACC program and the ADC pipeline.
• Over the quarter, the stock traded in a relatively narrow range before the trial readout, with the entire decline concentrated around the early-October announcement.
• For more detailed data, explore ArriVent's Price Targets, Earnings, and Forecast pages.
• Investors can also explore Trending AI Robots for AI-driven trading insights.

ArriVent BioPharma (AVBP) Company Overview and Market Position

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company based in Newtown Square, Pennsylvania, focused on developing and commercializing precision oncology medicines. Its lead candidate, firmonertinib, is an oral, brain-penetrant, mutation-selective EGFR tyrosine kinase inhibitor licensed from Shanghai Allist Pharmaceuticals, with which ArriVent holds ex-China rights. The drug is already approved in China for certain EGFR-mutant non-small cell lung cancer (NSCLC) indications and was being advanced globally for EGFR exon 20 insertion and PACC mutations.

Beyond firmonertinib, ArriVent is building an antibody-drug conjugate (ADC) pipeline, including ARR-217, a CDH17-targeted ADC partnered with Lepu Biopharma for gastrointestinal cancers, and ARR-002, a dual-target MUC16/NaPi2b ADC. Investors follow the stock primarily for the firmonertinib data catalysts and the company's emerging ADC optionality.

ArriVent BioPharma (AVBP) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, AVBP has fallen approximately 45%, from a closing price of $28.45 on September 25, 2026 to around $15.70 in recent trading. The decline was abrupt: on October 6, 2026, shares dropped about 47% in a single session, from $28.46 to a close of $15.09, touching a 52-week low near $12.09 intraday on unusually heavy volume.

The quarterly trend tells a similar story. Through July, August, and September, the stock traded mostly in a $28 to $31 range as investors positioned ahead of the pivotal FURVENT readout. Because the stock was essentially range-bound before the early-October announcement, the quarterly decline of roughly 45–50% is almost entirely attributable to the same trial outcome that drove the 30-day move.

What Drove AVBP Stock Price in the Last 30 Days

The dominant catalyst was the failure of the global Phase 3 FURVENT trial. On October 6, 2026, ArriVent announced that firmonertinib monotherapy did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review in previously untreated patients with EGFR exon 20 insertion-mutated NSCLC. The 240 mg dose achieved median PFS of 11.0 months versus 9.5 months for platinum-based chemotherapy, with a hazard ratio of 0.75 that narrowly missed statistical significance.

Analysts attributed the miss in part to a stronger-than-expected chemotherapy control arm, which delivered roughly 9.5 months of PFS versus anticipated estimates of about 7.5 to 8 months. Secondary endpoints favored firmonertinib, including investigator-assessed PFS of 11.1 versus 7.1 months and a confirmed objective response rate of 60% versus 33%, with no new safety signals.

The news triggered a sharp re-rating. Multiple firms lowered their price targets, with Jefferies, Truist, and Guggenheim each moving their targets from around $45 to $18, and analysts removed the exon 20 insertion indication from their valuations. The stock subsequently staged a partial recovery before the late-October ESMO 2026 meeting, where ArriVent presented encouraging Phase 1 data for its ARR-217 ADC, showing a 44.8% objective response rate at the 6 mg/kg dose in heavily pretreated colorectal cancer patients.

What Drove AVBP Stock Performance Over the Last Quarter

For most of the quarter, AVBP traded sideways in the $28 to $31 range, reflecting a balance between optimism over the firmonertinib readout and overhangs such as a $250 million at-the-market offering program announced in May 2026. The company also reported second-quarter 2026 results in August, widening its net loss as research and development spending rose.

The quarter's defining event was the FURVENT failure, which removed a key near-term value driver and forced a fundamental reassessment of the lead program. That reassessment redirected investor attention toward firmonertinib's second pivotal opportunity, the ALPACCA trial in EGFR PACC-mutant NSCLC, and toward the ADC pipeline, including ARR-217 and ARR-002, the latter of which began dosing its first patient in October.

Trending AI Robots

Tickeron's Trending AI Robots page curates a focused selection of the platform's top-performing AI trading bots. While Tickeron offers hundreds of AI bots that trade thousands of tickers, only the most relevant and best-performing strategies appear in this section, helping traders filter signal from noise. The featured bots vary widely in strategy, timeframe, and performance metrics, ranging from short-term momentum approaches to longer-horizon technical and fundamental models. For investors tracking volatile biotech names, this curated view can provide a useful complement to traditional research. Exploring the page offers a practical way to see how automated, data-driven strategies are currently positioned across the market.

AVBP Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, the key question is how ArriVent reprioritizes its pipeline after the FURVENT outcome. Investors will monitor the company's review of the complete FURVENT dataset and any update on the future development path for firmonertinib. The ALPACCA Phase 3 trial in EGFR PACC-mutant NSCLC remains the drug's principal remaining late-stage opportunity.

On the ADC side, further ARR-217 Phase 1b dose-optimization data is expected in 2027, and the early clinical progress of ARR-002 will be closely watched. Financial factors also matter: a clinical-stage company with no product revenue faces ongoing cash burn, and its financing strategy will be important given the at-the-market program and rising R&D costs. Upcoming quarterly earnings and any regulatory or partnership updates will further shape the outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations